Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

By Crul M.   Rosing H.   de Klerk G.J.   Dubbelman R.   Traiser M.   Reichert S.   Knebel N.G.   Schellens J.H.M.   Beijnen J.H.   ten Bokkel Huinink W.W.  

European Journal of Cancer, Vol. 38, Iss. 12, 2002-08 ,pp. : 1615-1621

Elsevier

Access to resources Recommend Favorite

Antitumour Activity and Retinotoxicity of Ethyldeshydroxy-sparsomycin in Mice

By Hofs H.P.   Wagener D.J.T.   De Vos D.   Ottenheijm H.C.J.   Winkens H.J.   Bovee P.H.M.   De Grip W.J.  

European Journal of Cancer, Vol. 31, Iss. 9, 1995-09 ,pp. : 1526-1530

Elsevier

Access to resources Recommend Favorite

Antitumour activity of oxaliplatin in neuroblastoma cell lines

By Riccardi A.   Ferlini C.   Meco D.   Mastrangelo R.   Scambia G.   Riccardi R.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 86-90

Elsevier

Access to resources Recommend Favorite

HPMA Copolymer Platinates as Novel Antitumour Agents: In Vitro Properties, Pharmacokinetics and Antitumour Activity In Vivo

By Gianasi E.   Wasil M.   Evagorou E.G.   Keddle A.   Wilson G.   Duncan R.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 994-1002

Elsevier

Access to resources Recommend Favorite

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

By Ozawa  

European Journal of Cancer, Vol. 37, Iss. 17, 2001-01 ,pp. : 2275-2282

Elsevier

Access to resources Recommend Favorite